- Home
- PRGS vs MESO Comparison
PRGS vs MESO Comparison
Compare PRGS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGS
- MESO
- Stock Information
- Founded
- PRGS 1981
- MESO 2004
- Country
- PRGS United States
- MESO Australia
- Employees
- PRGS N/A
- MESO N/A
- Industry
- PRGS Computer Software: Prepackaged Software
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRGS Technology
- MESO Health Care
- Exchange
- PRGS Nasdaq
- MESO Nasdaq
- Market Cap
- PRGS 1.7B
- MESO 1.8B
- IPO Year
- PRGS 1991
- MESO N/A
- Fundamental
- Price
- PRGS $41.49
- MESO $17.36
- Analyst Decision
- PRGS Strong Buy
- MESO Strong Buy
- Analyst Count
- PRGS 5
- MESO 2
- Target Price
- PRGS $68.00
- MESO $24.00
- AVG Volume (30 Days)
- PRGS 566.5K
- MESO 181.7K
- Earning Date
- PRGS 09-29-2025
- MESO 08-28-2025
- Dividend Yield
- PRGS N/A
- MESO N/A
- EPS Growth
- PRGS N/A
- MESO N/A
- EPS
- PRGS 1.09
- MESO N/A
- Revenue
- PRGS $940,126,000.00
- MESO $17,198,000.00
- Revenue This Year
- PRGS $32.42
- MESO $440.77
- Revenue Next Year
- PRGS $1.44
- MESO $110.74
- P/E Ratio
- PRGS $37.70
- MESO N/A
- Revenue Growth
- PRGS 31.41
- MESO 191.39
- 52 Week Low
- PRGS $39.00
- MESO $9.61
- 52 Week High
- PRGS $70.28
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- PRGS 46.44
- MESO 62.39
- Support Level
- PRGS $39.14
- MESO $14.32
- Resistance Level
- PRGS $41.76
- MESO $15.61
- Average True Range (ATR)
- PRGS 1.12
- MESO 0.57
- MACD
- PRGS 0.06
- MESO 0.24
- Stochastic Oscillator
- PRGS 54.05
- MESO 89.97
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.